<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7935902/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Mouse models of genes implicated in Parkinson’s disease and their dopamine neurotransmission phenotypes.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Gene</th>
   <th colspan="1" rowspan="1" id="0-1-.">Model</th>
   <th colspan="1" rowspan="1" id="0-2-.">Motor symptom</th>
   <th colspan="1" rowspan="1" id="0-3-.">Dopamine neurotransmission phenotype</th>
   <th colspan="1" rowspan="1" id="0-4-.">Proposed role in DAT regulation</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td rowspan="4">SNCA</td>
   <td>mThy-1 human WT α-synuclein overexpression 
    <sup>
     <a ref-type="bibr" rid="CR112">112</a>
    </sup>
   </td>
   <td>L-Dopa responsive sensorimotor deficits</td>
   <td>Increased extracellular dopamine; increased dopamine turnover rate; lower striatal TH level</td>
   <td rowspan="4">Membrane microdomain targeting 
    <sup>
     <a ref-type="bibr" rid="CR121">121</a>
    </sup>, and surface insertion 
    <sup>
     <a ref-type="bibr" rid="CR25">25</a>, 
     <a ref-type="bibr" rid="CR122">122</a>
    </sup>. 
   </td>
  </tr>
  <tr>
   <td>(AAV6)– human WT α-synuclein 
    <sup>
     <a ref-type="bibr" rid="CR116">116</a>
    </sup>
   </td>
   <td>Age-dependent motor deficits</td>
   <td>Reduced striatal dopamine release and dopamine reuptake; reduced dopamine tissue levels;</td>
  </tr>
  <tr>
   <td>CaM-tTA human WT α-synuclein overexpression 
    <sup>
     <a ref-type="bibr" rid="CR115">115</a>
    </sup>
   </td>
   <td>Age-dependent motor deficit</td>
   <td>Significant reduction of dopamine level in the olfactory bulb; Trend towards reduced dopamine in striatum; loss of dopamine neurons in SN.pc</td>
  </tr>
  <tr>
   <td>MPrion human A53T α-synuclein overexpression 
    <sup>
     <a ref-type="bibr" rid="CR113">113</a>, 
     <a ref-type="bibr" rid="CR114">114</a>
    </sup>
   </td>
   <td>Motor hyperactivity</td>
   <td>Reduced DAT expression and dopamine reuptake; Increased dopamine content in striatal tissue; no evident loss of dopamine neuron in SN.pc</td>
  </tr>
  <tr>
   <td rowspan="5">LRRK2</td>
   <td>BAC human LRRK2 overexpression 
    <sup>
     <a ref-type="bibr" rid="CR176">176</a>
    </sup>
   </td>
   <td>Motor hyperactivity</td>
   <td>Elevated striatal dopamine release; comparable dopamine uptake and tissue dopamine content; no loss of dopamine neurons in SN.pc</td>
   <td rowspan="5">Long term axonal trafficking 
    <sup>
     <a ref-type="bibr" rid="CR132">132</a>
    </sup>, endolysosomal trafficking 
    <sup>
     <a ref-type="bibr" rid="CR149">149</a>
    </sup>
   </td>
  </tr>
  <tr>
   <td>BAC human LRRK2 R1441G 
    <sup>
     <a ref-type="bibr" rid="CR177">177</a>
    </sup>
   </td>
   <td>L-DOPA responsive motor deficits</td>
   <td>Reduced striatal dopamine release; no evident loss of dopamine neuron in SN.pc</td>
  </tr>
  <tr>
   <td>Human LRRK2 G2019S transgene 
    <sup>
     <a ref-type="bibr" rid="CR178">178</a>
    </sup>
   </td>
   <td>Age-dependent motor deficits</td>
   <td>Normal striatal dopamine level and turnover rate; Increased dopamine turnover rate in olfactory bulb; Age-dependent loss of dopamine neurons in SN.pc</td>
  </tr>
  <tr>
   <td>Mouse Lrrk2 R1441C knock-in 
    <sup>
     <a ref-type="bibr" rid="CR179">179</a>
    </sup>
   </td>
   <td>Decreased locomotor responses to quinpirole; reduced locomotor response to AMPH</td>
   <td>Normal striatal dopamine level; reduced catecholamine release; no loss of dopamine neurons in SN.pc</td>
  </tr>
  <tr>
   <td>Mouse Lrrk2 G2019S knockin 
    <sup>
     <a ref-type="bibr" rid="CR127">127</a>, 
     <a ref-type="bibr" rid="CR128">128</a>
    </sup>
   </td>
   <td>Early hyperactivity that declines with age 
    <sup>
     <a ref-type="bibr" rid="CR128">128</a>
    </sup>
   </td>
   <td>Reduced striatal dopamine release; trend of reduced DAT expression; age-dependent DAT dysfunction; increased dopamine turnover rate; no loss of dopamine neurons in SN.pc</td>
  </tr>
  <tr>
   <td>VPS35</td>
   <td>Mouse Vps35 D620N knockin 
    <sup>
     <a ref-type="bibr" rid="CR91">91</a>
    </sup>
   </td>
   <td>No evident motor symptoms</td>
   <td>Altered striatal dopamine release; reduced dopamine reuptake; reduced striatal DAT expression; no evident loss of dopamine neurons in SN.pc</td>
   <td>DAT endocytic sorting and recycling 
    <sup>
     <a ref-type="bibr" rid="CR89">89</a>, 
     <a ref-type="bibr" rid="CR91">91</a>
    </sup>
   </td>
  </tr>
  <tr>
   <td>PARKIN</td>
   <td>Mouse Parkin knockout 
    <sup>
     <a ref-type="bibr" rid="CR158">158</a>, 
     <a ref-type="bibr" rid="CR159">159</a>
    </sup>
   </td>
   <td>Reduced spontaneous motor activity</td>
   <td>Increased dopamine turnover; Increased extracellular dopamine; Reduced striatal dopamine release; reduced dopamine reuptake; no loss of dopamine neurons in SN.pc</td>
   <td>Protein quality control 
    <sup>
     <a ref-type="bibr" rid="CR26">26</a>
    </sup>; endolysosomal trafficking 
    <sup>
     <a ref-type="bibr" rid="CR155">155</a>, 
     <a ref-type="bibr" rid="CR156">156</a>
    </sup>
   </td>
  </tr>
  <tr>
   <td>RIT2</td>
   <td>Mouse 
    <i>Pitx3</i>
    <sup>
     <i>IRES2-tTA</i>
    </sup>
    <i>RIT2 knockout</i>
    <sup>
     <a ref-type="bibr" rid="CR30">30</a>, 
     <a ref-type="bibr" rid="CR166">166</a>
    </sup>
   </td>
   <td>Increased acute cocaine sensitivity in males, but decreased in females</td>
   <td>In females: reduced surface DAT expression in ventral striatum; In males: reduced total DAT levels; increased [ 
    <sup>3</sup>H] dopamine reuptake in striatal slices 
   </td>
   <td>DAT surface retention 
    <sup>
     <a ref-type="bibr" rid="CR29">29</a>
    </sup>
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p>The literature cited is not exhaustive. However, reduced DAT-mediated dopamine reuptake is frequently observed in mouse models without dopaminergic degeneration.</p>
 </tfoot>
</table>
